Update 2021: Management of Small Cell Lung Cancer

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

(2021) Stephen V. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

(2021) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

(2021) A.-M.C. Dingemans et al.   ANNALS OF ONCOLOGY

PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

(2021) L. Paz-Ares et al.   Journal of Thoracic Oncology

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

(2020) Abbie S. Ireland et al.   CANCER CELL

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

(2020) José Trigo et al.   LANCET ONCOLOGY

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

(2020) Davey Daniel et al.   INTERNATIONAL JOURNAL OF CANCER

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

(2020) Jonathan W Goldman et al.   LANCET ONCOLOGY

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

(2019) Andrés F. Cardona et al.   Frontiers in Oncology

Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis

(2019) Jia Zhong et al.   Thoracic Cancer

Current Diagnosis and Management of Small-Cell Lung Cancer

(2019) Shuhang Wang et al.   MAYO CLINIC PROCEEDINGS

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

(2019) Ludovic Fournel et al.   CANCER LETTERS

Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch

(2019) Youcef Ouadah et al.   CELL

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening

(2018) Anish Thomas et al.   CHEST

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

(2018) Anna F Farago et al.   Future Oncology

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

(2017) Toshiaki Takahashi et al.   LANCET ONCOLOGY

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival

(2017) E. Wakeam et al.   LUNG CANCER

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

(2017) Jing Shan Lim et al.   NATURE

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

(2016) J. E. Bisi et al.   MOLECULAR CANCER THERAPEUTICS

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

(2016) Mark D. Borromeo et al.   Cell Reports

Radiotherapy for extensive stage small-cell lung cancer – Authors' reply

(2015) Ben J Slotman et al.   LANCET

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

(2015) Ben J Slotman et al.   LANCET

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway

(2015) Fumihiko Murai et al.   Cell Discovery

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

(2014) Shigeki Umemura et al.   Journal of Thoracic Oncology

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study

(2013) Kaoru Kubota et al.   LANCET ONCOLOGY

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Survival outcomes with the use of surgery in limited-stage small cell lung cancer

(2010) David Schreiber et al.   CANCER

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer

(2010) James B. Yu et al.   Journal of Thoracic Oncology

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

(2010) J. Voortman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY